METHOD FOR TREATING CANCER WITH AN ORAL DOSAGE FORM OF AN ALPHA ESTROGEN RECEPTOR INHIBITOR

MX433674BActive Publication Date: 2026-05-19EISAI R&D MANAGEMENT CO LTD

View PDF 0 Cites 0 Cited by

Patent Information

Application Number: MX2021014349
Authority / Receiving Office: MX · MX
Patent Type: Patents
Current Assignee / Owner
Priority Date: 2019-05-28
Filing Date: 2021-11-23
Publication Date: 2026-05-19
Estimated Expiration: 2040-05-15

Application Information

Patent Timeline

28 May 2019

Priority

23 Nov 2021

Application

MX2021014349

19 May 2026

Publication

MX433674B

IPC: A61K31/4439; A61K9/20; A61K9/28; A61K9/48; A61K47/12; A61K47/26; A61K47/38; A61P35/00

CPC: A61K31/4439; A61K9/282; A61K9/2013; A61K9/2018; A61K9/2054; A61K9/2866; A61K9/4858; A61K9/4866

Get more patent work done with AI

Run novelty searches—or use them for FTO, design risk, drafting and technical problem-solving.

Explore More Agents

Novelty Search
Search existing technologies and assess novelty
↗
FTO
Analyze whether a product may infringe others' patents
↗
Design FTO
Check prior-design risk for exterior design
↗
Drafting
Draft patent application text based on a technical solution
↗
Find Solutions with TRIZ
Generate feasible solution to solve your technical challenge
↗
IP MCP Servers
Connect trusted patent search and cited evidence to Claude, Cursor or your own AI workflow
↗

Patent Text Reader

Abstract

The present invention relates to pharmaceutical compositions comprising a human ERA inhibitor and methods of cancer therapy using the ERA inhibitor. In particular, this document describes dosages of H3B-6545 with defined pharmacokinetic (PK) profiles that allow the inhibitor to be administered effectively and safely to a human subject in need thereof.

Need to check novelty before this filing date? Find Prior Art